Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
20.03
+1.26 (6.71%)
At close: Feb 13, 2026, 4:00 PM EST
20.40
+0.37 (1.85%)
After-hours: Feb 13, 2026, 7:54 PM EST
Zai Lab Revenue
Zai Lab had revenue of $116.10M in the quarter ending September 30, 2025, with 13.52% growth. This brings the company's revenue in the last twelve months to $441.63M, up 24.14% year-over-year. In the year 2024, Zai Lab had annual revenue of $398.99M with 49.59% growth.
Revenue (ttm)
$441.63M
Revenue Growth
+24.14%
P/S Ratio
4.88
Revenue / Employee
$236,292
Employees
1,869
Market Cap
2.24B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 398.99M | 132.27M | 49.59% |
| Dec 31, 2023 | 266.72M | 51.68M | 24.03% |
| Dec 31, 2022 | 215.04M | 70.73M | 49.01% |
| Dec 31, 2021 | 144.31M | 95.35M | 194.77% |
| Dec 31, 2020 | 48.96M | 35.97M | 277.04% |
| Dec 31, 2019 | 12.99M | 12.86M | 9,965.89% |
| Dec 31, 2018 | 129.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 825.94M |
| Telix Pharmaceuticals | 664.23M |
| Galapagos NV | 336.64M |
| Adaptive Biotechnologies | 276.98M |
| Wave Life Sciences | 109.23M |
| Ascentage Pharma Group International | 54.52M |
| Mesoblast | 17.20M |
| Dianthus Therapeutics | 3.08M |
ZLAB News
- 5 days ago - Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026 - Business Wire
- 12 days ago - Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter - Benzinga
- 4 weeks ago - Zai Lab Limited (ZLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 5 weeks ago - Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors - Business Wire
- 5 weeks ago - Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 7 weeks ago - Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia - Business Wire
- 2 months ago - Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis - Business Wire